Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
Top Cited Papers
Open Access
- 1 March 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (5) , 657-668
- https://doi.org/10.1086/499819
Abstract
The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investmeKeywords
This publication has 75 references indexed in Scilit:
- Challenges of Sexually Transmitted Disease Prevention and Control: No Magic Bullet, but Some Bullets Would Still Be AppreciatedClinical Infectious Diseases, 2005
- Lack of development of new antimicrobial drugs: a potential serious threat to public healthThe Lancet Infectious Diseases, 2005
- Antiinfective biotechs face partnering gapNature Biotechnology, 2005
- Taking inventory: antibacterial agents currently at or beyond Phase 1Current Opinion in Microbiology, 2004
- The Antibiotic Pipeline — Challenges, Costs, and ValuesNew England Journal of Medicine, 2004
- Trends in Antimicrobial Drug Development: Implications for the FutureClinical Infectious Diseases, 2004
- Antimicrobial drug development – the past, the present, and the futureClinical Microbiology & Infection, 2004
- Antimicrobial Resistance Trends and Outbreak Frequency in United States HospitalsClinical Infectious Diseases, 2004
- Development of drugs for antimicrobial-resistant pathogensCurrent Opinion in Infectious Diseases, 2003
- Why is big Pharma getting out of antibacterial drug discovery?Current Opinion in Microbiology, 2003